Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,732 across all filing types
Latest filing 2022-10-11 Regulatory Filings
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
111年9月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a company named 美時, providing information about loan balances and endorsement guarantees for the current and previous months. It contains tabular data on financial guarantees and limits but does not include comprehensive financial statements or detailed analysis. The document length is very short (619 characters), and it appears to be a regulatory disclosure or compliance update rather than a full financial report or announcement of a meeting or vote. There is no indication of an annual report, earnings release, management discussion, or other detailed filings. Given the nature and brevity, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2022-10-11 Chinese
111年9月營業收入
Regulatory Filings Classification · 90% confidence The document is a revenue summary report for a company named 美時 for the period 民國111年09月 (September 2022). It contains monthly and year-to-date net operating revenue figures with comparisons to the previous year and explanations for significant changes. The document is short (806 characters) and provides financial data but is not a full financial report like an annual or interim report. It appears to be a regulatory disclosure of monthly revenue figures, typical of a regulatory filing or a brief financial update. There is no indication that this is a full Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or other detailed report. It is more consistent with a Regulatory Filing (RNS) as a general disclosure of financial information without comprehensive analysis or full financial statements.
2022-10-11 Chinese
代重要子公司Alvogen Korea Co., Ltd.公告處分產品權利
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a listed company (美時) regarding a related party transaction involving the disposal of product rights by a subsidiary. It details the transaction specifics, counterparties, pricing, board approval, and accounting opinions. The document is relatively short (2607 characters) and focuses on disclosure of a specific transaction rather than a financial report or earnings release. It does not contain financial statements or comprehensive financial data. This type of document fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-09-27 Chinese
代子公司Lotus International Pte. Ltd.公告取得產品權利
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a listed company (美時) regarding a transaction by its subsidiary involving the acquisition of product rights. It details the nature of the transaction, parties involved, pricing, and approvals. The document is relatively short (2601 characters) and focuses on disclosure of a specific transaction rather than providing comprehensive financial data or a report. It does not contain financial statements or detailed analysis typical of financial reports like Annual Reports or Interim Reports. It is a regulatory disclosure about a related-party transaction, fitting best under Regulatory Filings (RNS) as it does not match other more specific categories such as Capital/Financing Update or Major Shareholding Notification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-09-27 Chinese
公告董事會決議通過增資新加坡子公司 Lotus International Pte. Ltd.
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from a listed company regarding a board resolution to increase capital in its Singapore subsidiary. It details the transaction specifics such as share quantity, price, total amount, and related party information. The content focuses on a capital increase transaction approved by the board, including financial figures and compliance disclosures. There is no indication of a full financial report, earnings release, or management discussion. The document is a regulatory announcement about a financing activity, specifically a capital increase in a subsidiary. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and it is not merely announcing a report publication, so it is not RPA or RNS. Confidence is high due to clear transaction details and board approval mention.
2022-09-27 Chinese
代重要子公司Alvogen Korea Co., Ltd.公告期中股利分派
Notice of Dividend Amount Classification · 100% confidence The document is a short announcement from a company (1795 美時) regarding the distribution of an interim dividend by its important subsidiary Alvogen Korea Co., Ltd. It specifies the board resolution date, the type and amount of dividend, and the record date. The content is focused on dividend payment details, which matches the definition of a Notice of Dividend Amount (DIV). The document length is only 507 characters, indicating it is a brief announcement rather than a full report. Therefore, the appropriate classification is DIV.
2022-09-20 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.